Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression-Introducing a novel prognostic model for bladder cancer recurrence

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 8, 2014, Pages 1178-1183

  Rausch, Steffen ^a   Hennenlotter, Jörg ^a   Todenhöfer, Tilman ^a   Aufderklamm, Stefan ^a   Schwentner, Christian ^a   Sievert, Karl Dietrich ^a   Stenzl, Arnulf ^a   Gakis, Georgios ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bladder cancer; Chronic kidney disease; Comorbidities; Creatinine; EGFR; Non muscle invasive; Prognosis

Indexed keywords

C REACTIVE PROTEIN; CREATININE;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON MUSCLE INVASIVE BLADDER CANCER; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RISK FACTOR; SEX; SMOKING HABIT; BLADDER TUMOR; BLOOD; CHRONIC KIDNEY FAILURE; DISEASE COURSE; DISEASE FREE SURVIVAL; KIDNEY; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CREATININE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84925944863     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.05.009     Document Type: Article

References (21)

1. Kirkali Z., Chan T., Manoharan M., et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005, 66(6 Suppl. 1):4-34. [accessed 15.07.12]. http://www.ncbi.nlm.nih.gov/pubmed/16399414.
2. Millán-Rodríguez F., Chéchile-Toniolo G., Salvador-Bayarri J., et al. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence. J Urol 2000, 164(3 Pt 1):680-684. [accessed 18.09.12]. http://www.ncbi.nlm.nih.gov/pubmed/10954628.
3. Babjuk M., Burger M., Zigeuner R., et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013, 64(4):639-653. [accessed 13.08.13]. http://www.ncbi.nlm.nih.gov/pubmed/23827737.
4. Sylvester R.J., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-477. [discussion 475-7], [accessed 28.09.13]. http://www.ncbi.nlm.nih.gov/pubmed/16442208.
5. Rink M., Xylinas E., Babjuk M., et al. Impact of smoking on outcomes of patients with a history of recurrent nonmuscle invasive bladder cancer. J Urol 2012, 188:2120-2127. [accessed 02.09.13]. http://www.ncbi.nlm.nih.gov/pubmed/23083868.
6. Saito K., Kihara K. Role of C-reactive protein in urological cancers: a useful biomarker for predicting outcomes. Int J Urol 2013, 20:161-171. [accessed 02.09.13]. http://www.ncbi.nlm.nih.gov/pubmed/22897628.
7. Xu X., Wu J., Mao Y., et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis of cohort studies. PLoS One 2013, 8:e58079. [accessed 08.09.13]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3589481&tool=pmcentrez&rendertype=abstract.
8. Palou J., Sylvester R.J., Faba O.R., et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012, 62:118-125. [accessed 29.09.13]. http://www.ncbi.nlm.nih.gov/pubmed/22101115.
9. Crivelli J.J., Xylinas E., Kluth L.A., et al. Effect of smoking on outcomes of urothelial carcinoma: a systematic review of the literature. Eur Urol 2013, 65(4):742-754. [accessed 02.09.13]. http://www.ncbi.nlm.nih.gov/pubmed/23810104.
10. Rink M., Furberg H., Zabor E.C., et al. Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. Eur Urol 2013, 63:724-732. [accessed 02.09.13]. http://www.ncbi.nlm.nih.gov/pubmed/22925575.
11. Gakis G., Todenhöfer T., Renninger M., et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int 2011, 108:1800-1805. [accessed 29.08.13]. http://www.ncbi.nlm.nih.gov/pubmed/21507193.
12. Yoshida S., Saito K., Koga F., et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int 2008, 101:978-981. [accessed 29.08.13]. http://www.ncbi.nlm.nih.gov/pubmed/18190628.
13. MacKenzie T., Zens M.S., Ferrara A., et al. Diabetes and risk of bladder cancer: evidence from a case-control study in New England. Cancer 2011, 117:1552-1556. [accessed 21.09.13]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3117102&tool=pmcentrez&rendertype=abstract.
14. Gupta N.P., Kolla S.B., Seth A., et al. Oncological and functional outcome of radical cystectomy in patients with bladder cancer and obstructive uropathy. J Urol 2007, 178(4 Pt 1):1206-1211. [accessed 08.09.13]. http://www.ncbi.nlm.nih.gov/pubmed/17698145.
15. Dash A., Galsky M.D., Vickers A.J., et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006, 107:506-513. [accessed 08.09.13]. http://www.ncbi.nlm.nih.gov/pubmed/16773629.
16. Wong G., Hayen A., Chapman J.R., et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol 2009, 20:1341-1350. [accessed 21.09.13]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2689896&tool=pmcentrez&rendertype=abstract.
17. Rouprêt M., Babjuk M., Compérat E., et al. European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 2013, 63:1059-1071. [accessed 23.09.13]. http://www.ncbi.nlm.nih.gov/pubmed/23540953.
18. Liu Y., Lu J., Hong K., et al. Independent prognostic factors for initial intravesical recurrence after laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma. Urol Oncol 2013, 32(2):146-152. [accessed 07.08.13]. http://www.ncbi.nlm.nih.gov/pubmed/23628312.
19. Morizane S., Iwamoto H., Masago T., et al. Preoperative prognostic factors after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Int Urol Nephrol 2013, 45:99-106. [accessed 02.09.13]. http://www.ncbi.nlm.nih.gov/pubmed/23229166.
20. Jørgensen L., Heuch I., Jenssen T., et al. Association of albuminuria and cancer incidence. J Am Soc Nephrol 2008, 19:992-998. [accessed 21.09.13]. http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2386729&tool=pmcentrez&rendertype=abstract.
21. Roth G.A., Lebherz-Eichinger D., Ankersmit H.J., et al. Increased total cytokeratin-18 serum and urine levels in chronic kidney disease. Clin Chim Acta 2011, 412:713-717. [accessed 23.09.13]. http://www.ncbi.nlm.nih.gov/pubmed/21195700.